Antibiotic Dosing Personalization for Critically Ill Adults
Official title: Antibiotic Model-Informed Precision Dosing in Critical Illness
Funded at Cincinnati Childrens Hosp Med Ctr · NIH-11360688 · Data updated 2026-11-12
Aims to personalize antibiotic dosing in critically ill adults using real-time drug levels and patient factors to improve outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | August 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $397,500 |
| NIH project number | 5R35GM146701-05 |
| Project ID | NIH-11360688 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older who are critically ill and receiving β-lactam antibiotics in an ICU setting.
✕Less likely to help
Patients not receiving antibiotics or not in the ICU care pathway may not benefit.
What this research studies
Clinically, critically ill adults show wide differences in how antibiotics behave in the body, making standard doses risky. This project plans to use real-time drug concentration data and population pharmacokinetic models to tailor β-lactam dosing for each patient. It focuses on identifying which patient groups benefit most from precision dosing and how to implement this approach in busy ICU settings without excessive cost. The work progresses toward safer, more effective antibiotic use and better survival for the sickest patients.
Why it matters
Potential benefit: If successful, it could lead to more effective infection control and fewer drug toxicities for critically ill adults.
How similar studies have gone: Prior work suggests variability in antibiotic PK/PD in critical illness; this program aims to fill remaining knowledge gaps and implement dosing strategies.
Where this research is happening
-
Cincinnati Childrens Hosp Med Ctr
Cincinnati, United States Active
Researchers
- Principal investigator: Tang Girdwood, Sonya C — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Tang Girdwood, Sonya C
Related research
Other NIH-funded projects on the same topics.
-
Glucocorticoids and critical illness outcomes in ICU patients
A researcher team at Columbia University will study how glucocorticoids affect short- and long-term outcomes for people who survive critical illness, including mental health and recovery aspects.
-
REPAIR-ICU: Understanding aging-like changes after critical illness to help ICU survivors
This grant studies how surviving an ICU stay triggers aging-related changes in the body and tests interventions to help people recover.
-
Understanding how individual responses to treatments vary in ARDS and sepsis
This grant aims to help clinicians predict which patients with ARDS or sepsis will benefit most from specific treatments by using advanced computer approaches.
-
Myeloid-Derived Suppressor Cells in Immunological Endotyping and Intervention for Chronic Critical Illness after Sepsis
Aimed at people who have survived sepsis after surgery, this grant seeks to understand why some patients develop long-term organ problems and how to tailor treatments to their immune responses.
-
Molecular rules of capillary leak in seriously ill kids
A study looking at why blood vessels become leaky in severely ill children and how that leads to organ failure.
-
Heme-Driven Immune Dysregulation in Critical Illness
Researchers are studying how free heme from red blood cell breakdown affects the immune system in people with sepsis or chronic blood disorders, with the aim of guiding better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.